Cancer Research

Clinical Trials Database

Category:
Enter keyword:
Search
36 Trial(s) displayed. Page 1 2 3 4   Next
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC (Galaxy 2)
Category:

This study is for people with advanced lung cancer (Stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC).

The standard of care treatment for this type of cancer is a chemotherapy called docetaxel. Ganetaspib is an experimental drug for the treatment of advanced lung cancer. It is thought that ganetespib may slow or stop lung cancer from growing. However, this has not yet been proven. The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced NSCLC.

You will be randomized into one of the study groups described below. Randomization means that you are put into a group by chance. A computer program will place you in one of the study groups. Neither you nor your study doctor can select which study group you will be in. You have an equal chance of being in either group.

There are two treatment groups: You will be randomly assigned to either Group 1 or Group 2.

  • Group 1: Standard of Care treatment - docetaxel alone given intravenously (IV, with a needle into the vein) for one hour once every 3 weeks. Each 3-week treatment period is called a "cycle".
  • Group 2: Standard of Care treatment with ganetespib. Ganetespib plus docetaxel each given IV on Day 1. You will receive ganetespib first by IV for one hour, followed by a 1-hour rest period. You will then receive docetaxel by IV for one hour. On Day 15, you will receive 150 mg/m2 ganetespib only by IV for one hour. Each 3-week treatment period is called a "cycle".
A phase II multicenter randomized trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or non-operative management: OPRA
Category:

This study is for people with cancer of the rectum that has extended through the rectal wall (Stage II), or involves the lymph nodes outside the rectum (Stage III) who have not yet had treatment.

Patients with rectal cancer are given chemotherapy with radiation therapy (chemoradiation), and then they have surgery to remove the rectum. Sometimes after surgery, patients will have standard chemotherapy. The extra chemotherapy is given to help make sure the tumor does not come back and to try and cure patients of their cancer.

The purpose of this study is to increase the number of patients cured from their rectal cancer by giving the chemotherapy before surgery instead of after surgery. Researchers also want to find out what are the effects, good and/or bad, of having chemotherapy before surgery has on you and your rectal cancer.

You will be "randomized" into one of the study groups described below. Randomization means that you are put into a group by chance. A computer program will place you in one of the study groups. Neither you nor your study doctor can select which study group you will be in. You have an equal chance of being in either group.

There are two treatment groups: You will be randomly assigned to either Group 1 or Group 2. In these treatment groups, both chemotherapy and chemoradiation will be given before surgery. When treatment is given before surgery it is called neoadjuvant treatment.

Group 1: Induction Neoadjuvant Chemotherapy (INCT) - Chemotherapy before chemoradiation

  • Chemotherapy: You will start by having 8 cycles of FOLFOX or 6 cycles of CapeOX. This part of the treatment will take approximately 16-18 weeks. Chemotherapy is given by an infusion into your vein.
  • Exams after Chemotherapy Approximately 2-6 weeks after completing chemotherapy, you will have a digital rectal exam, an endoscopic exam (looking into your rectum) called a proctoscopy or flexible sigmoidoscopy, and an MRI to monitor your tumor is recommended but not required.
  • If your surgeon discovers that your tumor has increased in size then you will be treated according to standard practice.
  • If your tumor has remained stable (same size) or decreased in size, then you will continue with study treatment.
  • Chemoradiation: If you continue with treatment, following the break you will have chemoradiation therapy for approximately 6 weeks. Along with the radiation you will receive either 5-FU or capecitabine. Your study doctor will see you periodically during the treatment to check your health status.
  • Exam after chemoradiation: Approximately 4-12 weeks after completing chemoradiation therapy, you will have a digital rectal exam and an endoscopic exam. You will also have a CT of the chest, abdomen and pelvis to make sure that the tumor will not have spread to other organs such as the liver or lungs. You will also have a rectal MRI to monitor your tumor. At this time, your surgeon will decide if you need surgery right away of if you can continue observation:
  • If your surgeon discovers that your tumor has not responded significantly to the chemotherapy and chemoradiation you will go straight to surgery. This is a standard surgical procedure that will not be modified for the purpose of the study.
  • If your surgeon discovers that your tumor has responded significantly or disappeared completely, then she/he will continue to follow you and watch your tumor to make sure that it continues shrinking until it disappears, or that it continues to stay away if it has disappeared. This is called non-operative management. During the endoscopic exam your surgeon may be uncertain whether the tumor has disappeared or not. He/she may decide to take a biopsy to see if there are cancer cells left.

Group 2: Consolidation Neoadjuvant Chemotherapy (CNCT) - Chemoradiation before chemotherapy

  • Chemoradiation: You will start by having approximately 6 weeks of chemoradiation therapy. Along with the radiation you will receive either 5-FU or capecitabine. Chemotherapy is given by an infusion into your vein.
  • Exam after chemoradiation: Approximately 2-6 weeks after completing chemoradiation therapy, you will have a digital rectal exam, an endoscopic exam (looking into your rectum) called a proctoscopy or flexible sigmoidoscopy, and an MRI to monitor your tumor is recommended but not required.
  • If your surgeon discovers that your tumor has increased in size then you will be treated according to standard practice.
  • If your tumor has remained stable (same size) or decreased in size, then you will continue with study treatment.
  • Chemotherapy: If you continue with trea
A Phase II/III Trial of Neoadjuvant FOLFOX, With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision: NCCTG 1048 “PROSPECT"
Category:

This study is for people with cancer of the rectum who have not yet had treatment.

The standard treatment for locally advanced rectal cancer involves chemotherapy and radiation, known as 5FUCMT, (the chemotherapy drugs 5-fluorouracil/capecitabine and radiation therapy) prior to surgery. Although radiation therapy to the pelvis has been a standard and important part of treatment for rectal cancer and has been shown to decrease the risk of the cancer coming back in the same area in the pelvis, some patients experience undesirable side effects from the radiation.

The purpose of this study is to compare the effects, both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy using a combination regimen known as FOLFOX, (the drugs 5-fluorouracil (5-FU), oxaliplatin and leucovorin) and selective use of radiation treatment, depending on response to the FOLFOX. The drugs in the FOLFOX regimen are all FDA (Food and Drug Administration) approved and have been used routinely since 2002 to treat patients with advanced colorectal cancer.

You will be "randomized" into one of the study groups described below. Randomization means that you are put into a group by chance. A computer program will place you in one of the study groups. Neither you nor your study doctor can select which study group you will be in. You have an equal chance of being in either group. All of the study drugs used in both groups have been FDA-approved for the treatment of colorectal cancer.

There are two treatment groups: You will be randomly assigned to either Group 1 or Group 2.

Group 1: chemotherapy & selective use of combination of chemotherapy and radiation therapy before or after surgery.

  • You will receive FOLFOX chemotherapy once every two weeks. On the first day of the cycles (Day 1), you will be given leucovorin and oxaliplatin through a catheter placed in a vein in your arm (intravenously or IV) for 2 hours and also 5- fluorouracil IV via continuous infusion. This is one cycle; you will receive 6 cycles total over a period of 12 weeks.
  • After completing FOLFOX chemotherapy, you will have an MRI scan or endorectal ultrasound (ERUS) to examine the tumor and how it has changed. If the tumor has decreased in size by at least 20% from before you started chemotherapy, you will proceed directly to surgery. If the tumor has not shrunk in size by 20%, you will receive radiation with chemotherapy. This is exactly the same treatment that will be given to the patients in Group 2.
  • A pathologist will study the tumor removed during surgery using a microscope. If all borders of the tumor are normal and do not contain any tumor, this means that all the tumor could be removed during surgery and it is recommended that you receive six additional cycles of FOLFOX chemotherapy. If all borders of the tumor are not normal and contain some small amount of tumor, this means that the entire tumor could not be removed during surgery, and it is recommended that you receive chemotherapy and radiation therapy for 5.5 weeks after your surgery. The chemotherapy and radiation therapy that you will receive if all of the tumor could not be removed is exactly the same treatment that will be given to the patients in Group 2. After 5.5 weeks of chemoradiation (5FUCMT), additional cycles of FOLFOX or similar chemotherapy will be recommended for 4 cycles or 8 weeks.

Group 2: preoperative chemotherapy and radiation therapy with additional chemotherapy after surgery

  • You will receive chemotherapy and radiation therapy for 5.5 weeks. You will be given either 5-fluorouracil IV via continuous infusion or Capecitabine doses taken orally twice daily, 5 days per week, on days of planned radiation therapy.
  • After the chemotherapy and radiation therapy is completed, you will proceed directly to surgery.
  • After surgery, it is recommended that you receive FOLFOX chemotherapy once every two weeks. On the first day of the cycles (Day 1), you will be given leucovorin and oxaliplatin IV for 2 hours and also 5-fluorouracil IV by continuous infusion. This is one cycle; you will receive 8 cycles total over a period of 16 weeks. The FOLFOX chemotherapy is the same as for Group 1. What is different is the timing and when it is given – before or after surgery.
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous DendriticCells(DC) Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Category:

A Study of Vaccine (DCVax®-L) to treat Newly Diagnosed GBM Brain Cancer - This study is for people with newly diagnosed Glioblastoma Multiforme (GBM). The purpose of this study is to determine if adding a vaccine called DCVax®-L to your standard treatment of surgery, radiation therapy and chemotherapy can slow the growth and recurrence of your brain tumor.

To be eligible for this study, you must be:

  • Recently diagnosed with GBM and your doctor is planning for you to have surgery to remove all or most of their tumor, followed by the standard radiation therapy and chemotherapy.
  • Are between 18 to 70 years old

The vaccine is made from your own cells that are taken from your blood and made into a vaccine after it has been processed.

The study involves a series of injections under your skin, given in your upper arm with either the active vaccine (DCVax®-L) or placebo vaccine (an inactive drug of salt water injection that has no treatment value). There is a 2 out of 3 chance of receiving the active vaccine vs. the placebo. Patients receiving the placebo vaccine who have tumor progression during treatment can switch to the active vaccine.

The vaccine (DCVax®-L) or placebo is supplied free of charge. You will receive a total of 5-10 vaccines, 2 injections for each time dose. Vaccines will be given at various intervals over two and a half years. You will be followed for a total of three years from the time you have your first vaccine.

This study is randomized, which means you are automatically assigned by a computer to receive either the active vaccine or the placebo vaccine. Neither you nor your doctor can choose which treatment you will get. This study is also double-blinded, thus both you and your doctor will not know which vaccine you are receiving.

A Treatment of Unresectable Hepatocellular Carcinoma with TheraSphere® (Yttrium-90 Glass Microspheres): An HDE Treatment Use
Category:

TheraSphere treatment for inoperable liver cancer - This clinical trial is being conducted to provide access to TheraSphere treatment to patients with liver cancer who cannot be treated by surgical removal of the tumor.  Treatment with TheraSphere selectively gives a radioactive material to tumor site (s) in the liver of patients with hepatocellular carcinoma

Based on experience gained in previous studies and well-established interventional radiology techniques, this protocol allows multiple treatments with TheraSphere® that may be delivered on an inpatient or outpatient basis. Patients may receive a single dose to the whole liver, or treatments delivered as a sequence of treatments approximately 30 - 90 days apart. A specific plan will be developed for each patient, based upon the presenting condition of the patient, the blood vessel anatomy, and the desired goal of treatment.  Tumor response rates will be measured as well as patients experience and toxicities associated with TheraSphere® treatment. 
Adenoma and Second Primary Prevention Trial SWOG 0820 (PACES)
Category:

This study is for people with a history of Stage 0, I, II, or III colon cancer that has been treated with surgery alone (at least one year ago) or in combination with chemotherapy and who no longer have cancer.

The purpose of this study is to determine if eflornithine and sulindac, taken alone or in combination, can decrease the risk of high-risk adenomas (colorectal adenomas are tiny growths in the colon that may eventually lead to cancer) or second primary colorectal cancers in patients who have been previously treated for Stage 0, I, II, or III colon cancer. ("Second primary colorectal cancer" means a new colorectal cancer developing within the colorectum.)

The study drugs eflornithine and sulindac are tablets which are taken orally. Sulindac is commercially available but is not approved for this indication. Oral eflornithine is an investigational agent and not approved by the FDA.

You will be randomized into one of the study groups described below. Randomization means that you are put into a group by chance. A computer program will place you in one of the study groups. Neither you nor your study doctor can select which study group you will be in. You have an equal chance of being in either group. This is a double-blind study, which means neither you nor the study team will know to which of these study drug groups you are assigned.

There are four treatment groups: You will be randomly assigned to either Group 1, Group 2, Group 3 or Group 4:

Group 1:placebo eflorinthine & placebo sulindac

  • You will take two (light tan) eflornithine placebo tablets once a day and one (golden-yellow) sulindac placebo tablet once a day. Placebo tablets look identical to the eflornithine and sulindac tablets, but they do not contain any medication.

Group 2: eflorinthine & placebo sulindac

  • You will take two (light tan) eflornithine tablets once a day and one (golden-yellow) sulindac placebo tablet once a day. The placebo tablet looks identical to the sulindac tablet, but it does not contain any medication.

Group 3: placebo eflorinthine & sulindac

  • You will take two (light tan) eflornithine placebo tablets once a day and one (golden-yellow) sulindac tablet once a day. The placebo tablet looks identical to the eflornithine tablets, but they do not contain any medication.

Group 4: eflorinthine & sulindac

  • You will take two (light tan) eflornithine tablets once a day and one (golden-yellow) sulindac tablet once a day.

Aall study participants will be given a 3-month supply of study drugs along with an intake calendar where you will record the number of pills you take each day and any side effects.

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) Crizotinib in treating patients with stage IB-IIIA non-small cellllung cancer that has been removed by surgery and ALK fusion mutations (ALCHEMIST Treatment Trial) Erlotinib Hydrochloride in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery (ALCHEMIST Treatment Trial)
Category:

This study is for people with Stage IB-IIIA, non-squamous, non-small cell lung cancer (NSCLC) that has or will be removed by surgery.

The purpose of this research study is to examine surgically removed tumors from lung cancer patient for certain genetic changes, and to possbily refer these patients to a treatment study with drugs that may specifically target tumors that have these genetic changes.

A genetic test will be done to learn if your tumor has any of these genetic changes:

  • Genetic changes in ALK (this will be referred to as ALK)
  • Genetic changes in EGFR (this will be referred to as EGFR)

If your tumor is not found to have the genetic changes in ALK or EGFR, your doctor will provide you with other options for your care and you wil be followed for 5 years.

If your tumor has a genetic change in ALK, you may be eligible to participate in a treatment clinical trial called ALCHEMIST-ALK study (E4512), that will randomize you to receive either:

  • Group 1: standard treatment plus crizotinib (pill)
  • Group 2: standard treatment plus placebo (pill)

The purpose of the ALCHEMIST-ALK research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer. The addition of crizotinib may help prevent your cancer from returning, but it could also cause side effects.

If your tumor has a genetic change in EGFR, you may be eligible to participate in a treatment clinical trial called ALCHEMIST-EGFR study (A081105), that will randomize you to receive either:

  • Group 1: standard treatment plus erlotinib (pill)
  • Group 2: standard treatment plus placebo (pill)

The purpose of the ALCHEMIST-EGFR study is to compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug).

A placebo is a pill that looks like the study drug, but is inactive and does not contain the study drug. You will be randomized into one of the study groups described above. Randomization means that you are put into a group by chance. A computer program will place you in one of the study groups (ALK study if you have the ALK mutation or the EGFR study if you have the EGFR mutation). Neither you nor your study doctor can select which study group you will be in. You have an equal chance of being in either group. This is a double-blind study, which means neither you nor the study team will know to which study drug group you were assigned (active drug or the placebo).

All patients will be followed for 5 years.

Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma (A221101)
Category:

This supportive care trial is for people with Glioblastoma Multiforme (GBM) who are experiencing fatigue that is related to their cancer. Cancer related fatigue is a very common symptom in people with cancer. The purpose of this study is to see how well oral armodafinil works in reducing cancer-related fatigue in patients with high grade glioma. Armodafinil may help relieve fatigue in patients with high grade glioma.

You will be randomized into one of the study groups described below. Randomization means that you are put into a group by chance. A computer program will place you in one of the study groups. You will have a one in three chance of being placed in any group. Neither you nor your study doctor will know which group you are in (double-blinded treatment). This study uses a placebo in one of the groups. A placebo is an inactive substance that is not known to affect your cancer or cause harm. Using placebos helps researchers more clearly understand whether the active drug is safer and more effective than not taking a medication.

There are three groups:

Group 1: You will take an Armodafinil 150mg pill every morning for 8 weeks

Group 2: You will take a Placebo pill every morning for 8 weeks

Group 3: You will take an Armodafinil 250mg pill every morning for 8 weeks

All participants will complete a booklet of questionnaires at the end of week 4 and 8 to assess fatigue, memory and concentration. This generally takes less than 30 min to complete each time.

Bevacizumab With or Without an Anti-Endoglin Monoclonal Antibody in Treating Patients With Recurrent Glioblastoma Multiforme (GBM) - N1174
Category:

The purpose of this study is to compare any good and bad effects of using a combination of the chemotherapy drug, TRC105, with the standard chemotherapy drug bevacizumab to the usual approach of bevacizumab alone. The addition of TRC105 to bevacizumab could result in better tumor shrinkage but it could also cause more side effects. This study will allow the researchers to know whether this different approach is better, the same or worse than the usual approach. To be better, the TRC105 should increase life by six months or more compared to the usual approach.

The chemotherapy drug bevacizumab is already FDA approved for use in treating glioblastoma multiforme.

You will be randomized into one of the study groups described below. Randomization means that you are put into a group by chance. A computer program will place you in one of the study groups. Neither you nor your study doctor can select which study group you will be in. You have an equal chance of being in either group.

There are two groups:

Group 1: (Experimental Group). You will take the combination of study drug TRC105 with the usual approach chemotherapy drug bevacizumab. Both medications are given by an infusion into your vein on day 1, 8 & 11 during your first week, then on days 1 & 8 for all other weeks for as long as this treatment is effective in treating your disease. Each cycle is 2 weeks long.

Group 2: (Standard Treatment Group). You will take the usual approach chemotherapy drug bevacizumab alone. Bevacizumab is given by an infusion into your vein once every 2 weeks for as long as it is effective in treating your disease.

All patients will be followed for 3 years after completing study treatment.

BMS CA180-330: Studying Interventions for Managing Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY)
Category:

Data collection study for patients with Chronic Myeloid Leukemia - This data collection study is being conducted to obtain and analyze information on the treatment and management of patients with chronic phase chronic myeloid leukemia (CP-CML). This may help improve cancer treatment for future patients and provide a better understanding of the treatments that work best to treat CP-CML.

Patients must be receiving treatment with Imatinib (Gleevac), Dasatinib (Sprycel), or Nilotinib (Tasigna) which are tyrosine kinase inhibitors.